Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper.

British Journal of Cancer
Fabio GomesAndrea Luciani

Abstract

Immunotherapy with checkpoint inhibitors against programmed cell death receptor (PD-1) and programmed cell death ligand (PD-L1) has been implemented in the treatment pathway of patients with non-small cell lung cancer (NSCLC) from locally advanced disease to the metastatic setting. This approach has resulted in improved survival and a more favourable toxicity profile when compared with chemotherapy. Following the successful introduction of single-agent immunotherapy, current clinical trials are focusing on combination treatments with chemotherapy or radiotherapy or even other immunotherapeutic agents. However, most of the data available from these trials are derived from, and therefore might be more applicable to younger and fitter patients rather than older and often frail lung cancer real-world patients. This article provides a detailed review of these immunotherapy agents with a focus on the data available regarding older NSCLC patients and makes recommendations to fill evidence gaps in this patient population.

References

Dec 7, 1994·Journal of the National Cancer Institute·S B YellenW T Leslie
Nov 23, 2000·Nature·T B Kirkwood, S N Austad
Jan 16, 2002·Current Opinion in Clinical Nutrition and Metabolic Care·Cathryn A J Devons
Nov 1, 2002·The Lancet Infectious Diseases·Gaëtan Gavazzi, Karl-Heinz Krause
Feb 18, 2004·International Journal of Radiation Oncology, Biology, Physics·Sandra DemariaSilvia C Formenti
Aug 9, 2005·Critical Reviews in Oncology/hematology·Martine ExtermannUNKNOWN Task Force on CGA of the International Society of Geriatric Oncology
Jan 6, 2006·The Cancer Journal·Rishi SawhneyArash Naeim
Aug 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shinzoh KudohMasahiro Fukuoka
Apr 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carmela PepeUNKNOWN National Cancer Institute of Canada and Intergroup Study JBR.10
Jul 22, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin FrühFrances A Shepherd
Jul 22, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Celine S LagesClaire Chougnet
Jun 23, 2009·Trends in Immunology·Nan-Ping WengJorg Goronzy
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Aug 4, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Arti HurriaWilliam P Tew
Jun 12, 2012·International Journal of Radiation Oncology, Biology, Physics·David A PalmaGeorge Rodrigues
Jan 24, 2013·Journal of Leukocyte Biology·Chris P VerschoorDawn M E Bowdish
Feb 7, 2014·The Journal of Immunology : Official Journal of the American Association of Immunologists·Anne M WertheimerJanko Nikolich-Žugich
Jun 18, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L DecosterM Extermann
Jul 11, 2014·Biogerontology·Jon Hazeldine, Janet M Lord
Jul 30, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Arti HurriaUNKNOWN Cancer and Aging Research Group
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Jun 25, 2015·Nature Reviews. Cancer·Holly E BarkerKevin J Harrington
Sep 16, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J NaidooJ D Wolchok
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Jan 5, 2016·Journal of Geriatric Oncology·Grant R WilliamsHolly Holmes
Jul 13, 2016·Trends in Immunology·Midas SeydaStefan G Tullius
Jan 20, 2017·Nature·Daniel S Chen, Ira Mellman
Feb 6, 2017·Nature Reviews. Drug Discovery·Stephen CavnarValery Panier
Apr 12, 2017·Nature·Alexander C HuangE John Wherry
Jun 22, 2017·The New England Journal of Medicine·David P CarboneUNKNOWN CheckMate 026 Investigators
Aug 15, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nasser HannaGregory Masters
Aug 22, 2017·Experimental Gerontology·Ryan D MolonyRuth R Montgomery

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02142738
NCT02220894
NCT01905657
NCT02041533
NCT01642004
NCT01673867
NCT02008227
NCT02453282
NCT02125461
NCT02409342

Software Mentioned

G8
EliSpot

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Seminars in Respiratory and Critical Care Medicine
Joy Huang, Karen L Reckamp
American Society of Clinical Oncology Educational Book
Misty Dawn ShieldsBruna Pellini
Zhongguo fei ai za zhi = Chinese journal of lung cancer
Yan Xu, Mengzhao Wang
© 2021 Meta ULC. All rights reserved